Margin dodolan resik Cybin Corp (CYBN)

Cybin Inc. (CYBN) is developing a portfolio of psychedelic drugs, mitigating regulatory risks through various testing stages. The net profit margin confirms this potential, with the metric valued at 0.00. Top neuroscientists, attracted by research grants, ensure stability, while experienced management mitigates risk by strictly adhering to drug development timelines.
cybin.com (CYBN) - rincian metrik lan laporan keuangan
- rega saham lan konsensus proyeksi valuasi:
- rincian kapitalisasi pasar:
- indikator nilai aset resik miturut neraca:
- indikator beban utang lan likuiditas:
Rasio Total Utang marang Ekuitas Cybin Inc.|CYBN - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal Cybin Inc.|CYBN - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku Cybin Inc|CYBN - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Cybin|Indikator likuiditas cepet cybin.com
- indikator bathi lan kelipatan valuasi:
CYBN - Asil keuangan resik|Proyeksi bathi mangsa ngarep Cybin Inc.|CYBN - Koefisien rega marang bathi|Prakiraan rega marang bathi cybin.com|CYBN - Rega marang bathi kanthi panyesuaian wutah|Pangali EV/EBITDA Cybin|CYBN - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Cybin|CYBN - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan cybin.com|CYBN - Dinamika bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Cybin Inc.
- data dodolan lan asil:
- data indikator margin:
Analisis kabeh metrik perusahaan:Cybin Inc.

Cybin Inc. (CYBN) efficient clinical trial logistics directly impact net margin fluctuations, reflecting the company's ability to control substance delivery costs. This indicator is calculated as the ratio of net profit to total revenue, allowing investors to assess the balance between revenue and operating expenses to identify capital impairment risks in a timely manner.
Pesaing wigati
Alkermes (ALKS) - Margin resik|AVDL (Avadel Pharmaceuticals plc) - Margin resik|ATAI (atai Life Sciences NV) - Margin dodolan resik|GHRS: Tingkat bathi resik|Margin dodolan resik MNMD|CMPS: Margin bathi resik|Margin dodolan resik LBRX (LB Pharmaceuticals)|Tingkat bathi resik DRUG|VNDA: Rentabilitas dodolan miturut bathi resik|ANRO (Alto Neuro) - Rentabilitas dodolan resik|NRXP: Margin dodolan resik|Cingulate Inc. (CING) - Margin dodolan resik|SILO (silopharma.com) - Margin dodolan resik|CPHI: Tingkat bathi resik|Margin dodolan resik CMND|Margin dodolan perusahaan Psyence Bio|Margin resik SciSparc Ltd SPRC|seelostherapeutics.com (SEEL) - Margin resik|VRPX - Margin resik|Tingkat bathi resik KRTX (Karuna Therapeutics, Inc.)